Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 121,992

Document Document Title
WO/2017/024018A1
Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical...  
WO/2017/021305A1
The present invention relates to a composition of less than or equal to about 1% of pheromones useful to treat or prevent a behavioral stress problem of a non-human mammal. It also relates to a device comprising said composition and to a...  
WO/2017/023724A1
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment, prophylaxis, palliation or amelioration of diseases, conditions and/or symptoms re...  
WO/2017/023833A1
The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of ~95°F to ~98.5°F (~35°C to ~36.7°C) to mitigate and delay the early onset ...  
WO/2017/021438A1
The present invention relates to a selected amide of γ-hydroxybutyric acid, a process of manufacture and uses thereof. The invention also includes a pharmaceutical composition comprising an effective amount of the selected compound of t...  
WO/2017/021920A1
The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, ...  
WO/2017/021304A1
The present invention provides a pharmaceutical dosage form comprising oxycodone and naloxone (or pharmaceutically acceptable salts thereof) for use in the treatment of Bladder Pain Syndrome (BPS) and/or at least one, preferably at least...  
WO/2017/021963A1
A method of treating cancer in a subject is disclosed. The method comprises administering to the subject: (i) a therapeutically effective amount of an inhibitory agent that down-regulates an amount of a polypeptide selected from the grou...  
WO/2017/023361A1
The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in a...  
WO/2017/021319A1
The present invention deals with novel compounds which are reactivators of human acetylcholinesterase, pharmaceutical compositions comprising said compounds, and their use in the treatment of a nervous and/or respiratory failure due to i...  
WO/2017/021951A1
Provided are compositions which include N-methyl-d-aspartate receptor (NMDA-R) antagonists. Moreover, provided are methods for reducing the permeability of the blood- brain-barrier, in a patient, by administering to the patient, a compos...  
WO/2017/017363A1
The invention relates to a gaseous drug including xenon gas for use in treating impaired cholinergic synaptic transmission in humans. Impaired cholinergic synaptic transmission causes disease of the central nervous system of said humans,...  
WO/2017/018475A1
The present invention provides a preventive or therapeutic agent for diseases such as mood disorders, anxiety disorders, schizophrenia, autism spectrum disorders, and Alzheimer's disease, which involve group II metabotropic glutamate (mG...  
WO/2017/018336A1
The present invention addresses the problem of providing a safe antinflammatory agent that is efficacious for ameliorating and improving inflammatory symptoms and for preventing and treating inflammatory diseases and has little side effe...  
WO/2017/017186A1
The present invention relates to a compound selected from 5-hydroxymethyl-2-furfural (5HMF), a prodrug thereof, a derivative thereof, and a metabolite thereof, said derivative being capable of enhancing the affinity of hemoglobin to oxyg...  
WO/2017/020005A1
This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disord...  
WO/2017/018321A1
Provided is a method for manufacturing a patch that comprises a support and an adhesive layer laminated on the support, said method comprising: a step for mixing an acid addition salt of asenapine with a (meth)acrylic acid ester (co)poly...  
WO/2017/018322A1
The present invention provides an adhesive patch that is provided with a support body and an adhesive layer laminated upon one surface of the support body. The adhesive layer includes asenapine or a pharmaceutically acceptable salt there...  
WO/2017/020016A1
This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disord...  
WO/2017/016668A1
The present invention relates to amide derivatives having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions compr...  
WO/2017/020002A1
This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disord...  
WO/2017/016512A1
The present invention provides a crystalline form A of masitinib mesylate, a preparation method therefor and a medical use thereof. The hygroscopicity of crystalline form A is remarkably reduced. Therefore, it is convenient for medicamen...  
WO/2017/019532A1
Provided herein are methods of using cyclic pyranopterin monophosphate (cPMP) for the treatment of diseases or disorders in humans related to molybdenum cofactor deficiency (MoCD) type A wherein at least once per day the active ingredien...  
WO/2017/019565A3
The current invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly or...  
WO/2017/015774A1
The invention relates to a method for treating pain in mammals, in which pannexin function-inhibitor compounds, including carbenoxolone, probenecid and 10panx, are administered to an individual suffering from pain. The invention also rel...  
WO/2017/017452A1
The present invention provides a transdermal delivery system comprising (R)-dihydroetorphine, or a salt, hydrate or derivative thereof, wherein said system has a rapid onset of (R)-dihydroetorphine plasma concentration characterised by t...  
WO/2017/016880A1
The present invention relates to the use of a neurotoxin, especially botulinum toxin, for use as a medicament in the treatment of a personality disorder and/or a habit and impulse disorder and/or a conduct disorder, as well as to a metho...  
WO/2017/018495A1
In the present invention, a compound represented by formula (I) (where each symbol in the formula is the same as defined in the description) or a pharmaceutically acceptable salt thereof has excellent TRPA1 antagonist activity, and the c...  
WO/2017/016669A1
The present invention relates to substituted amide derivatives of formula (I) having dual pharmacological activity towards both the sigma (σ) receptor, and the p-opioid receptor, to processes of preparation of such compounds, to pharmac...  
WO/2017/017453A1
The present invention provides a transdermal patch comprising: a drug-containing layer comprising (R)-dihydroetorphine, or a salt or a hydrate thereof, and a poly(meth)acrylate; and a backing layer.  
WO/2017/019616A1
Compositions and methods for treating addiction in a subject are disclosed. In particular, compositions and methods for treating addiction to a dopaminergic psychostimulant are disclosed. In some embodiments, addiction is treated by agon...  
WO/2017/015049A1
Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Ch...  
WO/2017/015349A1
A combination of a muscarinic receptor antagonist consisting of a M2-receptor antagonist and of a non-selective, peripheral anticholinergic agent, and optionally an anticholinesterase inhibitor, and use of the same for treatment of hypoc...  
WO/2017/013599A1
A method of preventing, alleviating or treating traumatic brain injury in an individual comprises administering to the individual a therapeutically effective and physiologically acceptable amount of an agent capable of reducing the amoun...  
WO/2017/012579A1
Disclosed are substituted indole compounds and use methods and uses thereof. The present invention particularly relates to novel indole compounds and pharmaceutical compositions comprising the compounds, for inhibiting re-uptake of 5-hyd...  
WO/2017/014315A1
Provided is an EP2 agonist having a high safety. A compound represented by general formula (I) (wherein each symbol is as defined in the description), a salt thereof, an N-oxide derivative thereof, a solvate of the same or a prodrug of t...  
WO/2017/015491A1
A composition of matter comprising an adeno-associated virus (AAV) or other human compatible virus, encoding the gene for Sialidase Neu3, B3Galt4, St3Gal2, or combinations thereof, and a neuron specific promoter, wherein the composition ...  
WO/2017/012502A1
The present invention relates quinazolinone compounds of Formula (I), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses; wherein the compounds or pharmaceut...  
WO/2017/013492A1
The present disclosure provides compositions comprising 15-HEPE for use in treating and/or preventing cancer and neurological diseases in a subject in need thereof.  
WO/2017/012088A1
An extraction method for a bird's nest extract comprises: extracting a broken bird's nest aqueous solution for 30 minutes to 12 hours at the temperature of 30 to 60°C, and stirring and vacuumizing the solution at the same time; then adj...  
WO/2017/012576A1
Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for examp...  
WO/2017/012599A1
The present invention relates to 5-substituted-7-[4-(substituted)benzyl]amino-3- isopropylpyrazolo[4,3-d]pyrimidines of formula (I) which are effective inhibitors od cyclin- dependent kinases and exhibit strong anti-inflammatory properti...  
WO/2017/014162A1
The purpose of the present invention is to provide: an amyloid β fibril-decomposing agent which contains a naturally occurring substance as an active ingredient; a therapeutic or prophylactic agent for a disease associated with amyloid ...  
WO/2017/011863A1
The invention relates to disulfide-rich peptides derived from spider venom and their use, particularly as neuroprotective agents. The invention also relates to nucleic acid molecules encoding the peptides as well as constructs and host c...  
WO/2017/013496A1
The compound (-)-tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride ((-)-ANAVEX2-73, (-)A2-73, (-)AE 37) has been found to exhibit selectivity for sigma-1 (σ1) receptors and stronger agonist activity at the muscarinic...  
WO/2017/013498A3
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characteriz...  
WO/2017/014170A1
Provided are: a heterocyclic compound which has an HDAC-inhibiting activity and is useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancer, central nervous system diseases including...  
WO/2017/013498A2
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characteriz...  
WO2017009711A1
Phospholipid preparations for the improvement of sleep and/or treatment of sleep disorders. Methods of improving sleep and/or treating sleep disorders comprising administering the same.  
WO2016069801A8
Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include Bacteroides (e.g., B. fragilis, ...  

Matches 351 - 400 out of 121,992